◆
Centrally acting melanocortin receptor agonist (MC3R & MC4R) stimulating desire pathways.
Dose ranges reflect commonly studied amounts in published research models. This is not medical advice. For research use only. Not for human consumption.
Protocol Comparison
Research Dose Reference
Available in 10 mg
PT-141
Cognitive
Research dose range
0 mg0.5 mg1 mg1.5 mg2 mg
Standard research range
1.25 - 1.25 mg
Effective dose demonstrating statistically significant efficacy over placebo in clinical trials.
Research focus
Central melanocortin-mediated arousal & desire pathway
Observed window
On-demand onset: 30-60 min
Administration
Episodic administration at least 45 minutes prior to evaluation
Primary pathway
Hypothalamic MC3R / MC4R / Dopaminergic signaling
Dosing data referenced from Clayton et al. (2016) and Kingsberg et al. (2019) RECONNECT Phase III trials. Strictly for laboratory research use.
PROTOCOL BENEFITS
Engineered Outcomes
Central MC3R/MC4R AgonistCNS-Mediated DesireFDA-Studied Pathway
◆
Operates entirely via the central nervous system, independent of vascular or nitric oxide pathways.
◆
Validated in Phase 3 clinical trials with over 1,200 subjects for sexual motivation.
SCIENCE
How It Works.
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone (alpha-MSH). Unlike PDE5 inhibitors which act strictly peripherally on vascular smooth muscle, PT-141 directly activates melanocortin MC3R and MC4R receptors located in the hypothalamus and limbic system.
This central action initiates dopamine release in the medial preoptic area, directly stimulating the neurobiological circuits responsible for sexual desire and arousal.
WHAT TO EXPECT
Onset of action in research subjects is observed within 30 to 60 minutes. PT-141 is designed for episodic, on-demand evaluation rather than daily chronic accumulation.
PROTOCOL NOTE
Available in 10 mg sterile vials. Strictly for laboratory research use.
FAQ
Protocol Questions
How does PT-141 differ from PDE5 inhibitors like sildenafil?+
PT-141 acts centrally via hypothalamic melanocortin MC3R and MC4R receptors to engage sexual arousal pathways in the brain, unlike PDE5 inhibitors which act peripherally on vascular smooth muscle.
What is the typical time-to-onset observed in research models?+
Central signaling activity is measured within 30–60 minutes following administration, characteristic of an on-demand receptor agonist profile.